Spire Wealth Management Has $1.92 Million Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Spire Wealth Management trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,312 shares of the medical equipment provider’s stock after selling 1,031 shares during the period. Spire Wealth Management’s holdings in Intuitive Surgical were worth $1,918,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Indiana Trust & Investment Management CO raised its stake in Intuitive Surgical by 5.3% during the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock worth $222,000 after buying an additional 25 shares during the last quarter. Hoxton Planning & Management LLC raised its position in shares of Intuitive Surgical by 4.9% in the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 25 shares in the last quarter. First Affirmative Financial Network lifted its stake in shares of Intuitive Surgical by 2.7% in the 2nd quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after purchasing an additional 26 shares during the period. Advance Capital Management Inc. boosted its position in shares of Intuitive Surgical by 3.8% during the 1st quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock valued at $295,000 after purchasing an additional 27 shares in the last quarter. Finally, Perigon Wealth Management LLC grew its stake in Intuitive Surgical by 0.5% during the first quarter. Perigon Wealth Management LLC now owns 5,363 shares of the medical equipment provider’s stock worth $2,140,000 after purchasing an additional 27 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Insider Activity at Intuitive Surgical

In other news, Director Craig H. Barratt sold 2,496 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $402.89, for a total value of $1,005,613.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Craig H. Barratt sold 2,496 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $402.89, for a total value of $1,005,613.44. The disclosure for this sale can be found here. Insiders sold 55,552 shares of company stock worth $26,281,657 in the last ninety days. 0.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ISRG. Evercore ISI cut their price target on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a report on Friday, July 19th. BTIG Research raised their target price on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research note on Wednesday. Robert W. Baird upped their price target on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Morgan Stanley increased their price target on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Finally, Piper Sandler upped their target price on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Price Performance

ISRG stock traded up $5.46 during mid-day trading on Friday, hitting $492.63. 1,097,792 shares of the stock were exchanged, compared to its average volume of 1,235,701. The stock has a market capitalization of $175.06 billion, a price-to-earnings ratio of 88.92, a PEG ratio of 5.43 and a beta of 1.39. The business has a fifty day moving average price of $454.69 and a 200 day moving average price of $414.70. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $493.97.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the firm posted $1.18 earnings per share. The business’s revenue was up 14.5% compared to the same quarter last year. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.